Handelsbanken Fonder AB reduced its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 28.6% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 188,209 shares of the medical research company's stock after selling 75,454 shares during the quarter. Handelsbanken Fonder AB owned about 0.11% of IQVIA worth $33,181,000 at the end of the most recent quarter.
Several other institutional investors and hedge funds also recently bought and sold shares of IQV. Terra Alpha Investments LLC boosted its stake in IQVIA by 4.8% in the 1st quarter. Terra Alpha Investments LLC now owns 7,644 shares of the medical research company's stock worth $1,348,000 after purchasing an additional 347 shares during the period. GAMMA Investing LLC grew its stake in IQVIA by 56.3% during the first quarter. GAMMA Investing LLC now owns 2,197 shares of the medical research company's stock valued at $387,000 after acquiring an additional 791 shares in the last quarter. Harbor Capital Advisors Inc. bought a new stake in IQVIA during the 1st quarter worth approximately $482,000. Bruce G. Allen Investments LLC raised its position in shares of IQVIA by 178.4% in the first quarter. Bruce G. Allen Investments LLC now owns 323 shares of the medical research company's stock worth $57,000 after buying an additional 207 shares in the last quarter. Finally, Pallas Capital Advisors LLC grew its holdings in shares of IQVIA by 270.6% during the first quarter. Pallas Capital Advisors LLC now owns 5,629 shares of the medical research company's stock worth $992,000 after purchasing an additional 4,110 shares in the last quarter. 89.62% of the stock is owned by institutional investors.
IQVIA Stock Performance
NYSE IQV traded up $0.27 during trading hours on Thursday, hitting $159.10. The company had a trading volume of 413,158 shares, compared to its average volume of 1,607,858. The company has a market cap of $27.52 billion, a PE ratio of 21.21, a price-to-earnings-growth ratio of 1.99 and a beta of 1.28. IQVIA Holdings Inc. has a 1-year low of $134.65 and a 1-year high of $252.88. The business has a 50 day moving average of $147.21 and a 200-day moving average of $178.30. The company has a debt-to-equity ratio of 2.12, a quick ratio of 0.84 and a current ratio of 0.84.
IQVIA (NYSE:IQV - Get Free Report) last issued its earnings results on Tuesday, May 6th. The medical research company reported $2.70 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.63 by $0.07. The business had revenue of $3.83 billion during the quarter, compared to the consensus estimate of $3.77 billion. IQVIA had a return on equity of 28.81% and a net margin of 8.91%. The company's revenue for the quarter was up 2.5% on a year-over-year basis. During the same period in the prior year, the business posted $2.54 EPS. As a group, equities research analysts expect that IQVIA Holdings Inc. will post 10.84 EPS for the current year.
Analyst Ratings Changes
IQV has been the subject of several recent research reports. Robert W. Baird lowered their price target on shares of IQVIA from $195.00 to $161.00 and set a "neutral" rating for the company in a research note on Wednesday, May 7th. Barclays cut their price target on IQVIA from $170.00 to $165.00 and set an "equal weight" rating on the stock in a research note on Wednesday, May 7th. HSBC lowered shares of IQVIA from a "buy" rating to a "hold" rating and decreased their price objective for the stock from $260.00 to $160.00 in a report on Friday, April 25th. Hsbc Global Res downgraded shares of IQVIA from a "strong-buy" rating to a "hold" rating in a report on Friday, April 25th. Finally, UBS Group dropped their target price on IQVIA from $255.00 to $185.00 and set a "buy" rating on the stock in a research report on Wednesday, May 7th. Eight equities research analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $226.32.
Check Out Our Latest Analysis on IQVIA
About IQVIA
(
Free Report)
IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.
See Also
Before you consider IQVIA, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and IQVIA wasn't on the list.
While IQVIA currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
